Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laxxon’s LXM.5 Shows Positive Pilot PK Results for Parkinson’s Disease
Details : A new generation levodopa/carbidopa asset LXM.5 is being developed for the treatment of patients with parkinson's disease (PD).
Product Name : LXM.5
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LXM.2
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laxxon Medical Reports Positive PK Study Results for Oral GLP-1 Dosage
Details : LXM.2 is an once-daily oral, first-in-class GLP-1 agonist, currently being investigated for diabetes, metabolic syndrome and weight loss.
Product Name : LXM.2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2025
Lead Product(s) : LXM.2
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Recipient : Adare Pharma Solutions
Deal Size : Undisclosed
Deal Type : Partnership
Adare Pharma, Laxxon Partner to Advance 3D Printed Oral Dosage Forms
Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Recipient : Adare Pharma Solutions
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : LXM.2
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Laxxon Medical Develops Non-Invasive 3D Printed Oral GLP-1 Therapy
Details : LXM.2 is a 3D printed oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adults and pediatric patients 12 years and older with obesity.
Product Name : LXM.2
Product Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2024
Lead Product(s) : LXM.2
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?